|
Federal Register
Notices > Importers >
Kenco VPI
FR Doc E6-12256 [Federal Register: August 1, 2006 (Volume 71, Number 147)]
[Notices] [Page 43526] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01au06-90]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Prior to issuing a registration under 21
U.S.C. 952(a)(2)(B), and in accordance with 21 CFR 1301.34(a), this is
notice that on April 13, 2005, Kenco VPI, Division of Kenco Group Inc., 350
Corporate Place, Chattanooga, TN 37419, has made application to the Drug
Enforcement Administration (DEA) by letter to be registered as an importer of
Nabilone (7379), a basic class of controlled substance listed in Schedule II.
The company plans to import the listed controlled substance for distribution
to its customers.
Kenco VPI has been an importer of Schedule III-V controlled substances since
June 14, 2004. On April 14, 2005, the DEA added Schedule II to the firm's
importer registration. The DEA also added the drug code for Nabilone, a Schedule
II controlled substance, to the firm's registration on April 28, 2005. Both
amendments to the registration were made without benefit of the required legal
process for modifying the DEA registration. Kenco VPI is currently complying
with the legal requirements to register as a Schedule III importer. In addition
the firm was given authorization to import the Nabilone product into the United
States on May 12, 2005. The Nabilone product was approved by the Food & Drug
Administration on May 15, 2006. DEA has agreed to allow Kenco VPI to continue to
import the Nabilone product into the United States, while the firm is completing
the required legal process.
Any manufacturer who on April 13, 2005, was registered, or applying to be
registered with DEA to manufacture such basic class of controlled substance may
file comments or objections to the issuance of the proposed registration and
may, at the same time, file a written request for a hearing on such application
pursuant to 21
CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47. For purposes of this Notice, DEA has chosen recognized
applicable manufacturers registered on April 13, 2005, the date on which Kenco
submitted its initial request to have Nabilone added to its DEA importer
registration. By employing this date, DEA seeks to equitably address its initial
failure to publish Kenco's request to import Nabilone, while at the same time
allowing those entities that would have been in a position to request a hearing
on April 13, 2005, had DEA filed a timely notice, the right to request a
hearing.
Any such written comments or objections being sent via regular mail may be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal Register
Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301;
and must be filed no later than August 31, 2006.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21
CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice
published in the Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled substance
listed in Schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration pursuant
to 21 U.S.C. 958(a),
21 U.S.C. 823(a),
and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 26, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-12256 Filed 7-31-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|